TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Participation likelihood
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adjusted difference in sitting time at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clustered metabolic risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvements in cardiometabolic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: risk of delivery before 28 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: procedure-to-delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device-associated bloodstream infections per 1000 patient-days
Endpoint domain: Adverse events/effects
Primary endpoint: Hand hygiene compliance before aseptic procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine Disability Scores (MIDAS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Migraine-specific Quality of Life scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: EQ5D utility scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Attendance at EPC consultation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of Patient-Reported Outcomes (PRO)
Endpoint domain: Adverse events/effects
Primary endpoint: Self‐Rating Anxiety Scale (SAS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: World Health Organization Quality of Life‐BREF (WHOQOL‐BREF) scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Comfort dosing opioids
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EC50 values for ropivacaine in dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain relief after three months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EUROHIS-QOL 8 total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical working ability rating
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Psychological working ability rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cost per patient/year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean scores of REBOA skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intervention‐associated mortality
Endpoint domain: Mortality/survival
Primary endpoint: therapist-rated implementation and transformational leadership
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: implementation climate
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of patients with positive antidrug antibody (ADA) status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: stone-free rate (SFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: corneal nerve fiber density increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Douleur Neuropathique en 4 score decrease
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Average foveal reading speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical capacity measured by peak oxygen consumption (peak VO2; mL/kg/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptoms assessed by Beck Depression Inventory II (BDI‐II) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tissue injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biochemical stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of risks remembered
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: reduction in plasma levels of total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in plasma levels of LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in plasma levels of pro-inflammatory protein MCP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity of EUS and MRCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood ratio +
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protocol adherence
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Sealing ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate at 6 and 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent ischaemic stroke within 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy and safety of ECLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to CRPC
Endpoint domain: Mortality/survival
Primary endpoint: CSS
Endpoint domain: Mortality/survival
Primary endpoint: mean percentage change in vitiligo surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in absolute melanocyte count from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean VESTA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinically relevant ECFs detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in chest pain after therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number needed to screen (NNS) to avert one death from breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Time to taking rescue medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best observed clinical response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable pain management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of mirogabalin
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance with e-cigarette advertising regulations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of hypoglycemia < 70 mg/dl
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of the DIDP scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychometric performance of the DIDP scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of surgical site infections (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: complete or partial renal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean recovery days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall treatment cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: rate of progression to severe AP
Endpoint domain: Adverse events/effects
Primary endpoint: Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of sick leave
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relieving postpartum pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reducing fundal height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shortening the duration of lochia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAP-Hand score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of C. difficile infection
Endpoint domain: Mortality/survival
Primary endpoint: HIV self-testing uptake
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Pre-BD FEV1 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ACQ-5 score reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: general cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcomes in COVID-19 patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with post‐traumatic stress disorder
Endpoint domain: Adverse events/effects
Primary endpoint: 24-month cumulative event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: 24-month event-rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation rates in leadership development activities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completion rates of mental health literacy training
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients with fever
Endpoint domain: Adverse events/effects
Primary endpoint: Serum levels of inflammatory markers (TGF-β, IL-10, TNF-α, IL-1β)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of cardiovascular adverse events of special interest (CVAESI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of CVAESI resulting in hospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of PECS
Endpoint domain: Adverse events/effects
Primary endpoint: Understanding of the Guided Questions Tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in body weight from baseline to week 68
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ctDNA allele frequency (AF) as a risk factor for MVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients under control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high-grade intraventricular hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: spontaneous intestinal perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Postherpetic neuralgia (PHN) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: quality of life impact of weight loss
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical benefit in NAFLD and insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived involvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preferences for target vegetables
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean R2 values for tumor motion curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total anxiety measured by the Beck Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tumor-shrinking rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: one-repetition maximum (1RM) in leg-press exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: one-repetition maximum (1RM) in chest-press exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: one-repetition maximum (1RM) in knee extension exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incident SAF events
Endpoint domain: Mortality/survival
Primary endpoint: SAFB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fast AF occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: severe secondary airway injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Vertical tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-exercise perspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Self-management score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: percentage of peak HR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FS rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: laboratory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time until CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time for tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: residual limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Parent-psychosocial score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent-function score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Parent-surgery score improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: perceived body image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Drug exposure (measured by AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain flares
Endpoint domain: Adverse events/effects
Primary endpoint: Breast MRI use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discussion of chemoprevention or breast MRI with provider
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Reduction in 100% fruit juice consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal childbirth satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: length of the active and second phases of parturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: mean bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child restraint system use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of allogeneic blood cell transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of postoperative incision infection
Endpoint domain: Adverse events/effects
Primary endpoint: knee flexor rate of torque development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee flexor impulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Pelvic Organ Prolapse Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MUP duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSFI desire domain subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural anxiety level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leakage on 24-h pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cure of urge incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of endoscopically detected esophageal lesions (EDEL)
Endpoint domain: Adverse events/effects
Primary endpoint: time spent in moderate to vigorous physical activity (MVPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of moderate to vigorous physical activity (MVPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of step counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequencies of severe CCRT‐associated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Global QOL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients returning to baseline global QOL score at 6-month
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bone fusion rate at 6 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral blood flow (CBF) in the thalamus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Willingness to discuss switching generic drugs
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Willingness to prescribe generic drugs
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Dose-dependent metabolomic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: N-terminal pro-B-type natriuretic peptide (NT-proBNP) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion (ROM) at 12th week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of Daily Living (ADL) score in MHQ at 24th week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Grip strength at 12th week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability of vericiguat
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of anticoagulant care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unplanned intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: average length of stay
Endpoint domain: Resource use
Primary endpoint: Reduction in alanine aminotransferase (ALT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in aspartate aminotransferase (AST) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in liver stiffness by vibration-controlled transient elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactivation of BCG scar
Endpoint domain: Adverse events/effects
Primary endpoint: Days to achieve 50% pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical Range of Motion (CVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence rate to educational and physical exercise sessions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Timing of the first ANC visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: overall health literacy score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage of patients requiring intraoperative Fentanyl
Endpoint domain: Adverse events/effects
Primary endpoint: Calcium release from pellicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pellicle thickness and density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-erosive potential of enamel pellicle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma glucose recovery within 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma glucose >70 mg/dL (3.9 mmol/L) or neuroglycopenic symptom relief within 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean time to achieve plasma glucose >70 mg/dL (3.9 mmol/L) or increase ≥20 mg/dL (1.1 mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma AA concentrations (AUC0‐180)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion difficulty of the assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early improvement in negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Poor attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Poor impulse control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lack of insight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of severe asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Usage of HIVST kits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of HIVST kits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite outcome of major bleeding and cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes